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Abstract 
 
Zinc is an essential microelement; its importance to skin is shown by severe skin symptoms in 
hereditary or acquired zinc deficiency, by the improvement of several skin conditions using 
systemic or topical zinc preparations and by the induced intracellular zinc release upon UVB 
exposure, which is the main harmful environmental factor to skin. Understanding the 
molecular background of the role of zinc in skin may help to gain insight into the pathology of 
skin disorders and to provide evidence for the therapeutic usefulness of zinc supplementation. 
Herein, we studied the effect of zinc chloride (ZnCl2) exposure on the function of HaCaT 
keratinocytes, and we found that a non-toxic elevation in the concentration of extracellular 
zinc (100 µM) facilitated cell proliferation and induced significant alterations in the mRNA 
expression of NOTCH1, IL8, and cyclooxygenase-2. In addition, we detected increased heme 
oxygenase-1 (HMOX1) expression and non-toxic generation of superoxide in the first 4 h. 
Regarding the effect on UVB-induced toxicity, although the level of cyclobutane pyrimidine 
dimers in keratinocytes pre-treated with zinc for 24 h was reduced 3 h after UVB irradiation, 
we found significantly enhanced superoxide generation 10 h after UVB exposure in the zinc 
pre-exposed cells. The overall survival was unaffected; however, there was a decrease in the 
percentage of early apoptotic cells and an increase in the percentage of late apoptotic plus 
necrotic cells. 
Our results suggest that exposure of human keratinocytes to non-toxic concentrations of 
ZnCl2 impacts gene expression, cell proliferation and the response to environmental stress in 
skin. It would be important to further examine the role of zinc in skin and to further clarify if 
this issue can affect our thinking about the pathogenesis of skin diseases.  
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1. Introduction 
 
Zinc is an essential microelement, and its importance in skin is shown by the severe skin 
symptoms of hereditary or acquired zinc deficiency, including erythaematous rashes, scaly 
plaques, and ulcers at orifices and acra 
1, 2
, and by the ability of systemic or topical zinc 
preparations to improve hair loss, acne and several inflammatory skin conditions 
3
. 
Zinc content of the body is associated with skin by approximately 9%, primarily with the 
epidermis (50–70 μg g−1 dry weight) 4, 5, and 50% of the available zinc is localised to the 
cytoplasm, while 30–40% is localised in the nucleus, and the remainder is associated with the 
plasma membrane 
6
. The cellular level and distribution of zinc is tightly controlled by zinc 
importers and transporters 
7
. The metallothionein (MT)/thionein couple sequester or release 
zinc depending on the local redox state, thereby influencing the function of numerous 
proteins, transcription factors and enzymes 
8
. An imbalance in the MT protein level can be 
detected in different skin cancers, in squamous cell carcinoma and in malignant melanoma 
9, 
10
. Indeed, the prevalence of genes encoding zinc proteins is estimated to be over 3% of the 
32,000 identified genes 
3
. According to Schwartz et al., over 300 zinc-dependent enzymes 
have been identified and characterised 
11
. A close relation between redox homeostasis and the 
regulation of different protein functions by zinc can provide an important, fine-tuned control 
mechanism in the cell, but this process has been evidenced biochemically and has not been 
well studied in biological systems. On the other hand, zinc exposure of skin keratinocytes via 
cosmetic products, sunscreens and dermatological topical treatment occurs daily 
4, 12
. The 
toxic effects of zinc pirithion and zinc oxide on the epidermis have been demonstrated 
13, 14
; 
however, it is not known whether nontoxic zinc exposure can impact the physiological 
functions of keratinocytes or influence the effects of other environmental factors. 
Ultraviolet light B (UVB) irradiation of human skin is known to induce pathophysiological 
processes such as oxidative stress and inflammation and is regarded as the main pathogenic 
factor of skin cancer development. UVB causes skin cell damage directly by inducing the 
production of cyclobutane pyrimidine dimers (CPDs) and indirectly by triggering the 
production of reactive species and interfering with cellular redox homeostasis. Importantly, 
rapid intracellular elevation of zinc levels occurs in keratinocytes after UVB irradiation 
15, 16
, 
and the level of MT is higher in the epidermis after acute UV exposure, while the skin of MT 
knockout mice is more susceptible to UVB 
17
. Previously, it was found that solar (i.e., mixed) 
UV irradiation of keratinocytes exposed to zinc chloride (ZnCl2) enhances cell survival and is 
able to reduce the immediate DNA damage 
18, 19
 and DNA fragmentation after exposure 
20
. In 
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this study, we aimed to obtain further experimental evidence on the effect of Zn (II) 
exposure on human keratinocyte function in conventional culture and under stressed 
conditions using UVB irradiation, the main environmental harmful factor to skin.  
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2. Materials and methods 
 
2.1. Cell culture, UVB-irradiation apparatus, and ZnCl2 treatment 
 
HaCaT human keratinocytes were obtained from ATCC and maintained in high-glucose 
DMEM (PAA, Traun, Austria) supplemented with 10% foetal bovine serum ((FBS) Lonza, 
Verviers, Belgium), 2 mM L-glutamine (PAA, Traun, Austria), 100 U/mL penicillin G, 0.1 
mg/mL streptomycin sulphate, and 0.25 μg/mL amphotericin B (Sigma-Aldrich, St. Louis, 
MO, USA) in an atmosphere of 5% CO2 at 37°C. In the UV irradiation experiments, the 
culture medium was replaced with sufficient phosphate-buffered saline (PBS) (DPBS, Lonza, 
Verviers, Belgium) to avoid dehydration. The cells were then exposed to UVB (20 mJ/cm
2
) 
using a TL20W/12 RS broadband, filtered UVB lamp (Philips, Germany), which had an 
emission spectrum of 280–370 nm, with a peak at 312 nm. The UV intensity was controlled 
with a UV light meter (UVP Inc., San Gabriel, USA). The original medium was replaced after 
treatment. A 0.1-M stock solution of ZnCl2 (Sigma-Aldrich, St. Louis, MO, USA) was 
prepared in deionised water and sterilised with a 0.2-µm sterile filter. A working 
concentration of 100 µM (unless stated otherwise) was selected according to previous reports 
20
.  
 
2.2. Apoptosis assay 
 
Cells were pre-treated with ZnCl2 for 24 h and then exposed to UVB. Afterward, apoptosis 
was measured 24 h after UVB exposure. Harvested cells (5 x 10
5
) were washed in ice-cold 
PBS and stained with Annexin V and propidium iodide (PI) using the Vybrant apoptosis assay 
Kit (Invitrogen, Eugene, Oregon, USA) according to the manufacturer’s protocol. The stained 
cells were analysed by flow cytometry (CyFlow® Space, Partec, Canterbury, United 
Kingdom) using UV/488 nm dual-excitation, measuring the fluorescence emission at 530 and 
575 nm. Annexin V
-
PI
-
 cells were identified as viable cells, Annexin V
+
PI
-
 cells were 
identified as early apoptotic cells, and the sum of the Annexin V
+
PI
+
 and Annexin V
-
PI
+
 cells 
was identified as late apoptotic plus necrotic cells. 
 
2.3. Cell proliferation 
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Cells were treated with 50 or 100 µM ZnCl2 for 72 h, and cell proliferation was measured 
using the EZ4U assay (Biomedica, Vienna, Austria) according to the manufacturer’s 
instructions. The optical density (OD) was determined at 450 nm using an Anthos 2020 
microplate reader (Biochrom Ltd., Cambridge, UK). 
 
2.4. Cyclobutane pyrimidine dimer (CPD)-ELISA 
 
Cells were treated with ZnCl2 for 24 h and/or UVB irradiated, and genomic DNA was 
purified 0, 1, 3, 6, and 24 h after UVB exposure using a QIAamp Blood Kit (Qiagen, Hilden, 
Germany). Ninety-six-well plates were coated with 0.003% protamine sulphate (Sigma-
Aldrich, St. Louis, MO, USA) for 2 days at 37°C. To measure CPD lesions, genomic DNA 
was diluted to 0.2 g/mL in PBS, denatured at 100°C for 10 min, and then chilled on ice for 
15 min. The denatured DNA solution was transferred to plates pre-coated with protamine 
sulphate and dried overnight at 37°C. For blocking, the plates were washed four times with 
PBS-T (0.05% Tween-20 in PBS) and then incubated in 20% FBS for 30 min at 37°C. The 
wells were then washed four times with PBS-T and incubated with the primary CPD antibody 
(#TDM-2, Cosmo Bio Co. Ltd., Tokyo, Japan) at a 1:1000 dilution in PBS for 30 min at 
37°C. The wells were then washed and incubated with the HRP-conjugated anti-mouse IgG 
secondary antibody (BioRad, Hercules, CA, USA) diluted 1:3000 in PBS for 30 min at 37°C. 
After incubation, the cells were washed four times with PBS-T and then once with citrate-
phosphate buffer (pH 5.0). Following buffer removal, the wells were incubated with a 
substrate solution (o-phenylene diamine (Sigma-Aldrich, St Louis, MO, USA), H2O2, and 
citrate-phosphate buffer (pH 5.0)) for 10 min at 37°C, at which time the enzyme reaction was 
stopped with 2 M H2SO4. The absorbance was measured using an Anthos 2020 microplate 
reader (Biochrom Ltd., Cambridge, UK) at 492 nm, and the OD values of the untreated cells 
were subtracted from those of the treated cells.  
 
2.5. TaqMan Low-Density Array (TLDA) 
 
Cells were treated with ZnCl2 for 4 or 24 h, and relative gene expression was measured. In a 
parallel experiment, cells were pre-treated with ZnCl2 for 24 h and then UVB irradiated. Six 
hours after exposure, total RNA was isolated using Trizol Reagent (MRC Inc., Cincinnati, 
Ohio, USA), and total RNA was quantified using a Nanodrop 2000 (Thermo Fisher Scientific, 
Wilmington, USA). cDNA was then synthesised using the High-Capacity cDNA Reverse 
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Transcription kit (Applied Biosystems, Foster City, CA, USA) according to the 
manufacturer’s instructions. We designed Custom TaqMan Array Microfluidic Cards (384-
well) by first selecting 91 genes based on their roles connected to zinc and the UVB response. 
The selected genes were involved in cell cycle progression, inflammation, apoptosis, DNA 
repair, and antioxidant defence (Supplementary 1). Genes connected with zinc homeostasis 
and some with an identified MRE in the promoter region were also added. The TLDA was 
performed using an Applied Biosystems 7900HT Real-Time PCR System according to the 
manufacturer’s protocol. cDNA (100 ng) in 100 μL of 1X Taqman Gene Expression Master 
Mix (Applied Biosystems, Foster City, CA, USA) was loaded into each port of the TLDA 
plates, and each sample was examined in pairs. The PCR program used for amplification was 
as follows: 94°C for 1 min; 40 cycles of 94°C for 12 sec; and 60°C for 45 sec. The data were 
derived from three independently performed experiments and were analysed using SDS 2.1 
software. ACTB, GAPDH, SDHA, and PGK1 were used for normalisation. Relative gene 
expression values were calculated using the 2
-ddCt 
method 
21, 22
.  
 
2.6. Measurement of superoxide (O2
•−
) production 
 
After 4 or 24 h of ZnCl2 treatment or after 24 h of ZnCl2 treatment combined with UVB, the 
production of O2
•−
 was measured using a dihydroethidium (HE) assay (Sigma-Aldrich, St. 
Louis, MO, USA) 1, 4, 10, and 24 h after UVB exposure. A working solution of HE at a 2 M 
final concentration was added to the cells and then incubated for 30 min at 37°C. The cells 
were then harvested, and the fluorescence intensity was measured by flow cytometry with a 
FACSCalibur (BD Biosciences, San Jose, USA) to determine the fluorescence intensity at 450 
nM, with 620 nm as a reference. The production of O2
•−
 was expressed as the mean of HE-
fluorescence intensity 
23
. 
 
2.7. Detection of hydrogen peroxide 
 
After 4, 10 or 24 h of ZnCl2 treatment, hydrogen peroxide production was determined using 
an Amplex red (10-acetyl-3,7-dihydroxyphenoxazine) assay. In this assay, a working solution 
of Amplex Red (Invitrogen, Eugene, Oregon, USA) at a 50-M final concentration and 
horseradish peroxidase (Sigma-Aldrich, St. Louis, MO, USA) at a 0.1 U/ml final 
concentration was added to the cells and then incubated for 20 min at room temperature. 
Fluorescence was subsequently read, with excitation at 530 nm and emission at 590 nm, using 
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a Fluoroskan Ascent FL plate reader (Thermo Scientific, Vantaa, Finland). The MFI values of 
untreated cells were subtracted from those of the treated cells. 
 
2.9. Western blotting 
 
Cells were treated with ZnCl2 for 4, 24, 48 or 72 h and lysed in RIPA buffer (Sigma-Aldrich, 
St. Louis, MO, USA). The protein concentration was then estimated using a BCA protein 
assay kit (Pierce Biotechnology, Rockford, USA). Proteins (20 g) were separated on 10 or 
12% SDS-polyacrylamide gels and then transferred onto nitrocellulose membranes by 
electroblotting. The membranes were then blocked with 5% low-fat milk in TTBS (0.1% 
Tween-20 in Tris-buffered saline) or in PBST (0.05% Tween-20 in PBS) and incubated 
overnight with primary antibody against heme oxygenase-1 (HMOX1) (#ab13248, Abcam 
Inc., Cambridge, USA) at 1:250 dilution or MTI/II (#ab12228, Abcam Inc., Cambridge, USA) 
at 1:1000 dilution in 5% milk at 4°C. The membranes were then washed and incubated with 
horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. After 
washing, the signals were visualised using ECL™ Prime Western Blotting Detection Reagent 
(GE Healthcare, Freiburg, Germany). -actin (Cell Signaling Technology Inc., Danvers, MA, 
USA) was used for normalisation. 
 
2.10. Statistics 
 
Statistical analysis was performed using GraphPad Prism Software 5.03 (GraphPAD Software 
Inc., San Diego, CA, USA), and p values were calculated using a 2-tailed Student's t test. 
Statistical significance was accepted when p<0.05. 
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3. Results 
 
3.1. Zn (II) increased cell proliferation 
 
To examine the effect of Zn (II) exposure on cell proliferation, HaCaT cells were treated with 
Zn (II) at concentrations of 50 and 100 µM in growth medium containing 10% FBS, and the 
effects were measured using an EZ4U assay. We found that 72-h treatment with 100 µM Zn 
(II) resulted in significantly increased cell proliferation (1.3-fold; p=0.045) (Figure 1). 
 
3.2. Zn (II) exposure impacted the expression of genes involved in zinc homeostasis, 
antioxidant defence, cell viability and inflammation in HaCaT cells 
 
Then, we identified genes that showed altered expression in response to 100 µM Zn (II)-
containing medium using TaqMan Low-Density Array analysis. We detected six significantly 
up-regulated genes with relative expression levels of at least 1.5-fold in Zn (II)-treated cells 
compared to the untreated controls (Table 1). The MT1F gene showed the highest 
overexpression at both time points following Zn (II) treatment (40.86-fold at 4 h; 12.92-fold 
at 24 h), and MT1X and HMOX1 were expressed more than 10-fold higher in treated cells 
after 4 h of Zn (II) exposure. The expression levels of MT1E, MT2A and SLC30A1 also 
showed at least a 2-fold significant difference between treated and untreated cells at both 
treatment times. The notch homolog 1, translocation-associated (Drosophila) (NOTCH1) 
gene was slightly up-regulated (1.47-fold), and we detected slight but significant suppression 
of IL8, prostaglandin-endoperoxide synthase 2 (PTGS2), and cytochrome P450 1B1 
(CYP1B1) mRNA expression (0.63-fold, 0.68-fold, and 0.63-fold, respectively) after 4 h of 
Zn (II) treatment. Specific commercial antibodies against MT protein isoforms are not 
currently available, and the composite of MTI/II can only be investigated at the protein level. 
Western blot analysis demonstrated that Zn (II) treatment induced the production of MTI/II 
proteins with a maximum at 48 h (Figure 2a). 
 
3.3. Zn (II) exposure impacted the expression of HMOX1 and induced significant O2
•−
 
production 
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We also measured the protein expression of HMOX1 after 4 and 24 h of Zn (II) exposure 
(Figure 2b). Western blot analysis demonstrated that 4-h Zn (II) treatment induced the 
production of a 34-kDa HMOX1 protein.  
On the other hand, the induction of the antioxidant defence protein HMOX1 upon Zn (II) 
exposure prompted us to examine whether Zn (II) treatment can induce reactive oxygen 
species. We measured the generation of O2
•−
 in response to Zn (II) exposure in cells using a 
flow cytometry-based HE assay. Our data showed significant production of O2
•−
 after 4 h of 
Zn (II) treatment compared to the control (p=0.006) (Figure 3a). To further confirm our data, 
we investigated O2
•−
 dismutation by measuring the production of H2O2, and we found 
extracellular diffusion of H2O2 to the growth medium 24 h after Zn (II) treatment (p=0.019) 
(Figure 3b). 
 
3.4. Zn (II) pre-exposure decreased the amount of CPDs but enhanced UVB-induced O2
•−
 
generation 
 
To shed light on the mechanism of the zinc-mediated component of the UVB response, we 
characterised UVB-induced O2
•−
 generation and CPD formation after 24-h Zn (II) pre-
treatment. We examined the level of O2
•−
 in Zn (II) pre-treated, UVB-irradiated cells and in 
cells only exposed to UVB (Figure 3c). We observed an increase in O2
•−
 generation, with a 
significant plateau 10 h post-UVB irradiation compared to the control (p<0.001), and we 
detected a time-dependent decrease in the amount of CPDs after UVB irradiation. Zn (II) pre-
treatment changed both processes that were induced by UVB (Figure 3d). Our results showed 
that significantly less CPDs (by 19.64%) were detected 3 h after UVB irradiation in cells pre-
treated with Zn (II) for 24 h compared to cells exposed only to UVB (p=0.0082). However, at 
10 h post-UVB exposure, significant enhancement of superoxide generation was observed 
when comparing Zn (II) pre-treated, UVB-irradiated cells to cells only treated with UVB 
irradiation (p<0.001). 
 
3.5. Zn (II) pre-exposure altered the type of cell death after UVB irradiation, without 
influencing the overall survival 
 
To investigate the effect of reduced levels of CPDs but elevated O2
•−
 levels after Zn (II) pre-
treatment, flow cytometric apoptosis and EZ4U cell viability assays were used. We found that 
the cell survival did not change between Zn (II)-treated and control cells 24 h after UVB 
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irradiation (Figure 4a). Regarding control cells, the percentage of proliferating cells was 
88.69% and the viability of cells after UVB irradiation was decreased by 51.96%. Regarding 
Zn (II) exposure the percentage of proliferating cells was 91.71%, and Zn (II) pre-treatment 
did not impact the effect of UVB irradiation, the viability of cells was decreased by 50.64% 
(Figure 4b). On the other hand, Zn (II) pre-treatment significantly decreased the proportion of 
early apoptotic cells (Annexin V
+
PI
-
; by 5.94%, 0.57-fold change, p=0.0286) and significantly 
increased the population of late apoptotic plus necrotic cells (Annexin V
+
PI
+
 and Annexin V
-
PI
+
; by 4.61%, 1.12-fold change, p=0.0026) (Figure 4b). 
 
3.6. Zn (II) caused a transcriptional shift in the UVB-modulated expression of genes 
 
To determine the molecular mechanism behind the cellular response to the combined effects 
of Zn (II) and UVB exposure, we performed a TaqMan Low-Density Array analysis to 
characterise the gene expression changes in HaCaT cells pre-treated with Zn (II). We 
identified 39 differentially expressed genes in cells only submitted to UVB irradiation 6 h 
after exposure compared to non-irradiated control cells (Table 2; Supplementary 2). Twelve 
genes were expressed more than 2-fold higher in UVB-irradiated cells than in control cells, 
and TNF, PTGS2, and IL-8 showed the highest overexpression (>10-fold). We identified 27 
genes that were down-regulated in UVB-irradiated cells compared to the control cells; MT1E 
was the most repressed (0.12-fold). Furthermore, MTF1 levels were significantly decreased 
compared to the control (0.32-fold). We observed a modest modulation in gene expression 
when comparing Zn (II) pre-treated, UVB-irradiated cells to those that were only UVB-
irradiated. Zn (II) pre-exposure mainly reduced UVB-induced HIPK2 mRNA suppression and 
caused little modification of POLB and RAD51 mRNA levels, whose relative gene expression 
levels were repressed following UVB irradiation (<0.75-fold) but remained unchanged 
(0.761.5-fold change) when pre-treated with Zn (II).  
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4. Discussion 
 
The events involved in the regulation of zinc homeostasis are complex and incompletely 
understood 
24
. In the skin, zinc is related to physiological functions, as shown from the 
consequences of zinc deficiency 
1, 2
. The use of zinc-containing topical therapeutics is 
widespread due to its clear benefit on cutaneous regeneration and on various inflammatory 
skin conditions 
3
. UVB, the main harmful environmental factor in skin, induces intracellular 
zinc release in keratinocytes, suggesting a functional role of zinc in the UV stress response 
15, 
16
. 
Extracellular zinc is thought to enter the cell through plasma membrane zinc importers and 
then is transported via a muffler with high affinity for zinc (e.g., MT) to intracellular storage 
sites such as the endoplasmic reticulum 
25
. Passive diffusion of zinc across cell membranes is 
not possible 
26
. Bozym et al. 
27
 investigated the effect of cell culture medium on the 
intracellular Zn (II) concentration and found that both the type of cell and the medium 
influence the intracellular free Zn (II) level during exposure to a certain concentration of Zn 
(II) and that the toxicity of supplemented Zn (II) must be carefully investigated. Previous 
experiments have shown that the exposure of HaCaT keratinocytes to 100 μM ZnCl2 was non-
toxic to the skin cells 
28
, and we have not found this concentration to be toxic in our 
experimental conditions. Based on the calculations of Bozym et al. 
27, 100 μM Zn (II) 
treatment leads to an approximate 100-nM increase of intracellular Zn (II). We also 
investigated the mRNA expression of MT isoforms. More than 10 functional MT isoforms are 
present in humans and are classified into four groups; we analysed the mRNA expression of 
nine of the MT isoforms from the MT1 and MT2 groups in keratinocytes in our experiments 
29
. We detected the expression of four isoforms, namely MT2A, MT1X, MT1E, and MT1F. 
Zn (II) treatment significantly increased the mRNA expression of all four MT isoforms and 
SLC30A1 (Table 1.). Specific antibodies against the MT protein isoforms are not available; 
therefore, a composite of MTI/II can only be investigated at the protein level. Western blot 
analysis demonstrated that Zn (II) treatment induced the production of MTI/II protein in a 
time-dependent manner (Figure 2a). In addition, we investigated the cellular localisation of 
MTs and found that MTs were present mostly in the nuclei of control cells, but after 24 h of 
treatment with Zn (II), we detected high amounts of MTs in the cytoplasm of the cells (data 
not shown). The variability of the localisation of MTs upon Zn (II) exposure may reflect the 
expression of MT isoforms with distinct function. Previously, we found high MTI/II protein 
expression in the nuclei of benign nevus cells, while high levels of MTI/II were present also 
Metallomics 
 
 13 
in the cytoplasm of cells in malignant melanoma 
10
. In the present study we found a 
significant proliferation advantage upon 100 μM ZnCl2 exposure, in accordance with a 
previous study 
28. We also tested the effect of 50 μM ZnCl2 treatment, but the change in 
proliferation was not significant. Although the effects of zinc on intracellular signalling events 
are not completely known, a positive impact of Zn (II) on cell proliferation might be 
attributed, at least in part, to the inhibition of phosphatases, leading to augmented protein 
tyrosine phosphorylation 
30
. The proliferation advantage by Zn (II) treatment can also be a 
consequence of increased calcium uptake 
31
 or up-regulated gene expression (e.g., NOTCH1, 
see Table 1) 
32,33
. Interestingly, in aged skin, which is characterised by decreased epidermal 
renewal, the expression of MT is lower 
34
. 
The mechanism of action of zinc impact on cell signalling is not well understood 
25
; herein, 
we found that zinc might affect reactive oxygen species (ROS)-sensitive signalling pathways. 
This is the first report demonstrating high expression of HMOX1 in cultured human 
keratinocytes upon nontoxic Zn (II) exposure (Figure 2b). The HMOX1 gene encodes an 
important member of the phase-II enzymes, which have cytoprotective roles in ROS 
scavenging. Furthermore, HMOX1 was shown to prevent cell death and to have a role in the 
regulation of inflammation 
35-37
. Nontoxic generation of O2
•−
 with subsequent H2O2 release 
was detected during nontoxic Zn (II) exposure (Figure 3a and 3b) and could explain the 
HMOX1 expression. Although Zn (II) itself is reported to be an inducer of oxidative stress by 
promoting mitochondrial and extra-mitochondrial production of ROS 
15
, the generation of 
ROS at a nontoxic level upon Zn (II) exposure/release has not been described. Nevertheless, 
O2
•−
-producing NAD(P)H oxidases are activated in response to growth factors and 
oncogenes, and enhanced cell proliferation was observed upon ROS-inducing, low-dose 
photodynamic treatment 
38-42
. Therefore, simultaneous increases in cell proliferation and ROS 
levels are not conflicting. In addition, NADPH oxidase mediated the induction of NFκB and 
HMOX1 in human colon cancer cells 
43
 without inducing cell death. Furthermore, the immune 
response can be redox-regulated 
44
, and we have observed down-regulation of some pro-
inflammatory mediators, such as IL8 and PTGS2, which are partly regulated by redox-
sensitive transcription factors (e.g., AP-1) 
45
. 
UVB exposure is the primary risk factor in skin-tumour development 
46
. A role of zinc in the 
mechanism of UVB-induced cell death has already been proposed. Stork et al. 
15
 described 
that the elevation of intracellular zinc levels after UVB irradiation is proportional to the 
fraction of dying or dead cells, and they concluded that UVB-induced zinc release may be an 
important step in UVB-induced cell death pathways. The consequences of UVB-induced 
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direct (primarily CPDs) and indirect (free radical generation) DNA damage are cell cycle 
arrest, DNA repair, and the induction of cell death pathways causing sunburn, inflammation, 
immunosuppression, and melanogenesis in the skin 
47
. We measured both the CPD level and 
superoxide generation (Figure 3c and 3d). Due to DNA repair processes, the amount of CPDs 
was decreased with time, and cells with unrepaired DNA damage were eliminated by 
apoptosis (Figure 4b). Similar to the results of Saito et al., pre-treatment of cells with Zn (II) 
for 24 h was not sufficient to improve cell survival (Figure 4a), although the level of induced 
CPD was lower in these cells 3 h after UVB irradiation 
48
. We assume that MT could exert 
some effect on CPD formation because partial translocation of MTs to the nucleus was 
observed 3 h after UVB irradiation (data not shown). Nevertheless, when further analysing 
cell death at 24 h post-UVB irradiation, when UVB-induced apoptosis is maximal 
49
, we 
found that the fraction of early apoptotic cells decreased, while the fraction of late apoptotic 
plus necrotic cells increased in Zn (II) pre-treated cells (Figure 4b). In the context of our 
results, the elevation of intracellular zinc levels after UVB irradiation that was described by 
Stork et al. was proportional to the fraction of dying or dead cells 
15
. When investigating the 
course of ROS production, the increase in superoxide production upon UVB treatment 
occurred at a maximum of 10 h, but unexpectedly, this was augmented by Zn (II) pre-
exposure (Figure 3c). It has recently been described that a vicious circle of ROS-induced zinc 
release and zinc-driven mitochondrial ROS production is an important neuronal cell death 
mechanism 
50
. On the other hand, it has been reported that the induction of a type of cell death 
other than apoptosis in cancer cells might increase the immunogenic potential of cell death 
51, 
52
. Whether a change in the death process upon Zn (II) pre-exposure can affect the immune 
response to UV-damaged cells, which would impact the development of various pathologies, 
e.g., autoimmunity or cancers, must be further studied. 
Zinc is redox inert metal. Observed changes in ROS might be attributed to the molecular 
effects of Zn (II) interactions with cysteinyl thiols, which alters protein functionality and 
thereby their reactivity and participation in redox reactions 
8
. It seems worthy to further 
examine the role of zinc in skin because further clarification of this issue can affect our 
thinking about the pathogenesis of skin diseases and can help identify new therapeutic targets.  
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Figure 1. Effect of Zn (II) exposure on cell proliferation in HaCaT keratinocytes. 
HaCaT cells were treated with 50 or 100 µM ZnCl2 for 72 h, and cell proliferation was 
measured by an EZ4U assay. The data were derived from three independent experiments and 
are presented as the mean ± SEM. An asterisk indicates a significant difference between 
ZnCl2-treated and control cells at p<0.05, with a 2-tailed Student’s t test. 
 
 
Figure 2. Effect of Zn (II) exposure on the protein expression of MTI/II and HMOX1 
HaCaT cells were treated with 100 μM ZnCl2 for 4, 24, 48 or 72 h, and western blotting A for 
MTI/II and B for HMOX1 were performed. Actin B protein expression was used as a 
reference; the representative data of three independent experiments are shown.  
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Figure 3. Effect of Zn (II) exposure on the production of reactive oxygen species and on 
the UVB-induced DNA-damage response 
HaCaT cells were treated with 100 μM ZnCl2 for 4 or 24 h and A the production of O2
•−
 was 
analysed using a flow cytometry-based dihydroethidium assay. B Cells were exposed to 100 
μM ZnCl2 for 4, 10 or 24 h, and the production of H2O2 was measured using a fluorimetric-
based Amplex Red assay. The MFI values of untreated cells were subtracted from those of the 
treated cells. C HaCaT cells were treated with 100 μM ZnCl2 for 24 h followed by 20 mJ/cm
2
 
UVB irradiation, and the amount of CPDs was determined at 0, 1, 3, 6, and 24 h after UVB 
irradiation using a CPD-specific ELISA. The OD values of untreated cells were subtracted 
from those of the treated cells. D The production of O2
•−
 was measured by a flow cytometry-
based dihydroethidium assay 1, 4, 10, and 24 h after UVB treatment.  
The data were derived from three independent experiments and are presented as the mean ± 
SEM. An asterisk indicates a significant difference between ZnCl2-treated and control cells 
(A, B) or between the ZnCl2 and UVB combination treatment and cells only exposed to UVB 
(C, D) at p<0.05, using a 2-tailed Student’s t test. 
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Figure 4. Effect of Zn (II) exposure on the UVB-induced cell death  
HaCaT cells were treated with 100 μM ZnCl2 for 24 h followed by 20 mJ/cm
2
 UVB 
irradiation, and A cell survival was measured using an EZ4U assay 24 h after UVB. B The 
rate of apoptosis was investigated by flow cytometry using Annexin V and propidium iodide 
staining 24 h after UVB irradiation. V=viability; EA=early apoptosis; LA/N=late apoptosis 
plus necrosis. The data were derived from three independent experiments and are presented as 
the mean ± SEM, p values were calculated by 2-tailed Student's t test. 
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Gene Symbol 
fold change (2
-ddCt
) 
4 h after Zn (II) treatment 24 h after Zn (II) treatment 
MT1F 40.86 12.92 
MT1X 17.34 3.24 
HMOX1 15.33 1.56 
MT1E 7.30 2.12 
MT2A 6.44 3.03 
SLC30A1 6.41 2.48 
NOTCH1 1.47 1.06 
PTGS2 0.68 1.01 
IL8 0.63 0.92 
CYP1B1 0.63 1.32 
Table 1. Differentially expressed genes upon Zn (II) treatment 
The relative gene expression of the listed genes was measured in HaCaT cells treated with 
100 µM ZnCl2 relative to untreated cells by TLDA. Values greater than 1.5 but less than 0.75 
are highlighted in bold and indicate significant t-test results at p<0.05, using a 2-tailed 
Student’s t test.  
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fold change (2
-ddCt
) 
UVB 
≤ 0.5 ≥ 2 0.55 - 0.75 1.5 - 2 
0.76 – 1.5 
/not significantly 
different from 
control* 
Z
n
 (
II
) 
+
 U
V
B
 
≤ 0.5 
APC 
ATM 
ATR 
BCL2 
BCL2L1 
CCNF 
CHEK2 
ERCC3 
ERCC4 
IGF1R 
ITCH 
MDM2 
MSH2 
MSH6 
MT1E 
MTF1 
NOTCH1 
RAD52 
SKIL 
TP73 
TRIM26 
VEGFC 
XPC 
XRCC2 
XRCC3 
    
≥ 2 
 CCNE1 
CDKN1A 
FOS 
GADD45B 
HBEGF 
IL1B 
IL8 
JUN 
PTGS2 
SNAI2 
TNF 
ATF3 
  MT1F 
MT1X 
MT2A 
SLC30A1 
0.55 – 0.75 
ERCC5   CHEK1 
ERCC2 
SMUG1 
TREX1 
  
1.5 - 2 
    CEBPA 
CYP1A1 
DDIT3 
 
0.76 - 1.5 
/not significantly 
different from 
control* 
HIPK2   DDB2 
NTHL1 
POLB 
RAD51 
  
Table 2. Effect of Zn (II) pre-treatment on transcriptional changes induced by UVB 
irradiation 
Relative gene expression was measured 6 h after UVB irradiation in HaCaT cells exposed to 
20 mJ/cm
2
 UVB or pre-treated with 100 µM ZnCl2 for 24 h and then UVB irradiated relative 
to untreated cells, using TLDA.  
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Gene Symbol Assay ID Gene Name 
ACTB
l
 Hs99999903_m1 actin, beta 
AKT1
 b
 Hs00178289_m1 v-akt murine thymoma viral oncogene homolog 1 
APC
 b
 Hs01568269_m1 Adenomatous Polyposis Coli 
APEX
 d
 Hs00172396_m1 
APEX nuclease (multifunctional DNA repair 
enzyme) 1 
ATF3
a, b
 Hs00231069_m1 activating transcription factor 3 
ATM
 b
 Hs01112307_m1 ataxia telangiectasia mutated 
ATR
 b
 Hs00354807_m1 ataxia telangiectasia and Rad3 related 
BAD
 b
 Hs00188930_m1 BCL2-associated agonist of cell death 
BCL2
 b
 Hs00608023_m1 B-cell CLL/lymphoma 2 
BCL2L1
 b
 Hs00236329_m1 BCL2-like 1 
C11orf31
h,i
 Hs00415057_m1 chromosome 11 open reading frame 31 
CCNE1
 b
 Hs01026536_m1 cyclin E1 
CCNF
 b
 Hs00171049_m1 cyclin F 
CDKN1A
 b
 Hs00355782_m1 cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
CEBPA
 b, h
 Hs00269972_s1 CCAAT/enhancer binding protein (C/EBP), alpha 
CEBPB
 b
 Hs00270923_s1 CCAAT/enhancer binding protein (C/EBP), beta 
CHEK1
 b
 Hs00967506_m1 CHK1 checkpoint homolog (S. pombe) 
CHEK2
 b
 Hs00200485_m1 CHK2 checkpoint homolog (S. pombe) 
CYP1A1
k
 Hs00153120_m1 
cytochrome P450, family 1, subfamily A, 
polypeptide 1 
CYP1B1
k
 Hs00164383_m1 
cytochrome P450, family 1, subfamily B, 
polypeptide 1 
DDB1
 c
 Hs00172410_m1 damage-specific DNA binding protein 1, 127kDa 
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DDB2
 c
 Hs03044953_m1 damage-specific DNA binding protein 2, 48kDa 
DDIT3
 b
 Hs01090850_m1 DNA-damage-inducible transcript 3 
ERCC1
 c
 Hs01012158_m1 
excision repair cross-complementing rodent repair 
deficiency, complementation group 1 (includes 
overlapping antisense sequence) 
ERCC2
 c
 Hs00361161_m1 
excision repair cross-complementing rodent repair 
deficiency, complementation group 2 
ERCC3
 c
 Hs01554450_m1 
excision repair cross-complementing rodent repair 
deficiency, complementation group 3 (xeroderma 
pigmentosum group B complementing) 
ERCC4
 c
 Hs00193342_m1 
excision repair cross-complementing rodent repair 
deficiency, complementation group 4 
ERCC5
 c
 Hs00164482_m1 
excision repair cross-complementing rodent repair 
deficiency, complementation group 5 
FOS
 b
 Hs00170630_m1 FBJ murine osteosarcoma viral oncogene homolog 
GADD45B
 b
 Hs00169587_m1 growth arrest and DNA-damage-inducible, beta 
GAPDH
l
 Hs99999905_m1 glyceraldehyde-3-phosphate dehydrogenase 
GLI1
j
 Hs01110766_m1 GLI family Zinc (II) finger 1 
HBEGF
a, b
 Hs00181813_m1 heparin-binding EGF-like growth factor 
HIPK2
 b
 Hs00179759_m1 homeodomain interacting protein kinase 2 
HMOX1
i
 Hs01110250_m1 heme oxygenase (decycling) 1 
HSPA6
k
 Hs00275682_s1 heat shock 70kDa protein 6 (HSP70B') 
HSPD1
k
 Hs01941522_u1 heat shock 60kDa protein 1 (chaperonin) 
IGF1R
 b
 Hs00609566_m1 insulin-like growth factor 1 receptor 
IL10
a
 Hs00961622_m1 interleukin 10 
IL1B
a
 Hs01555410_m1 interleukin 1, beta 
IL1RN
a
 Hs00893626_m1 interleukin 1 receptor antagonist 
IL8
a
 Hs00174103_m1 interleukin 8 
ITCH
 b
 Hs00395201_m1 itchy E3 ubiquitin protein ligase homolog (mouse) 
JUN
 b
 Hs00277190_s1 jun proto-oncogene 
KRT10
j
 Hs00166289_m1 keratin 10 
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LCN2
h,i
 Hs01008571_m1 lipocalin 2 
MDM2
 b
 Hs00234753_m1 Mdm2 p53 binding protein homolog (mouse) 
MGMT
k
 Hs01037698_m1 O-6-methylguanine-DNA methyltransferase 
MMP9
a
 Hs00234579_m1 
matrix metallopeptidase 9 (gelatinase B, 92kDa 
gelatinase, 92kDa type IV collagenase) 
MSH2
e
 Hs00953523_m1 
mutS homolog 2, colon cancer, nonpolyposis type 1 
(E. coli) 
MSH6
e
 Hs00264721_m1 mutS homolog 6 (E. coli) 
MT1A
g,h
 Hs00831826_s1 metallothionein 1A 
MT1B
g,h
 Hs00538861_m1 metallothionein 1B 
MT1E
g,h
 Hs01938284_g1 metallothionein 1E 
MT1F
g,h
 Hs00744661_sH metallothionein 1F 
MT1G
g,h
 Hs02578922_Gh metallothionein 1G 
MT1H
g,h
 Hs00823168_g1 metallothionein 1H 
MT1M
g,h
 Hs00828387_g1 metallothionein 1M 
MT1X
g,h
 Hs00745167_sH metallothionein 1X 
MT2A
g,h
 Hs01591333_g1 metallothionein 2A 
MTF1
g
 Hs00232306_m1 metal-regulatory transcription factor 1 
NOTCH1
h,j
 Hs01062014_m1 notch 1 
NTHL1
 d
 Hs00959764_m1 nth endonuclease III-like 1 (E. coli) 
OGG1
 d
 Hs00213454_m1 8-oxoguanine DNA glycosylase 
PARP1
 d
 Hs00242302_m1 poly (ADP-ribose) polymerase 1 
PCNA
 c, d, e
 Hs00427214_g1 proliferating cell nuclear antigen 
PGK1
l
 Hs00943178_g1 phosphoglycerate kinase 1 
POLB
 d
 Hs01099715_m1 polymerase (DNA directed), beta 
PTGS2
a
 Hs00153133_m1 
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase) 
RAD23B
 c
 Hs00234102_m1 RAD23 homolog B (S. cerevisiae) 
RAD51
f
 Hs00153418_m1 
RAD51 homolog (RecA homolog, E. coli) (S. 
cerevisiae) 
RAD52
f
 Hs00172536_m1 RAD52 homolog (S. cerevisiae) 
RPA1
 c, f
 Hs00161419_m1 replication protein A1, 70kDa 
S100A7
a,j
 Hs00161488_m1 S100 calcium binding protein A7 
SDHA
l
 Hs00188166_m1 
succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp) 
SKIL
 b
 Hs01045418_m1 SKI-like oncogene 
SLC30A1
g,h
 Hs00253602_m1 
solute carrier family 30 (Zinc (II) transporter), 
member 1 
Metallomics 
 
 23 
SMUG1
 d
 Hs00204820_m1 
single-strand-selective monofunctional uracil-DNA 
glycosylase 1 
SNAI2
a
 Hs00950344_m1 snail homolog 2 (Drosophila) 
TNF
a
 Hs00174128_m1 tumor necrosis factor 
TNFAIP3
a
 Hs00234713_m1 tumor necrosis factor, alpha-induced protein 3 
TP53
 b
 Hs01034249_m1 tumor protein p53 
TP73
 b
 Hs01056230_m1 tumor protein p73 
TREX1
e
 Hs03055245_s1 three prime repair exonuclease 1 
TRIM26
a
 Hs00758189_m1 tripartite motif-containing 26 
TXN
i
 Hs01555212_g1 thioredoxin 
UNG
 d
 Hs00422172_m1 uracil-DNA glycosylase 
VEGFC
a
 Hs00153458_m1 vascular endothelial growth factor C 
XPA
 c
 Hs00166045_m1 xeroderma pigmentosum, complementation group A 
XPC
 c
 Hs01104206_m1 xeroderma pigmentosum, complementation group C 
XRCC1
 d
 Hs00959834_m1 
X-ray repair complementing defective repair in 
Chinese hamster cells 1 
XRCC2
f
 Hs03044154_m1 
X-ray repair complementing defective repair in 
Chinese hamster cells 2 
XRCC3
f
 Hs00193725_m1 
X-ray repair complementing defective repair in 
Chinese hamster cells 3 
XRCC6
f
 Hs00995282_g1 
X-ray repair complementing defective repair in 
Chinese hamster cells 6 
ZNRD1
k
 Hs00205908_m1 Zinc ribbon domain containing 1 
Supplementary 1. List of selected genes for TaqMan Low-Density Array analysis 
Undetermined genes are highlighted in bold. 
a
 Inflammation 
b
 DNA-damage response 
c
 Nucleotide excision repair 
d
 Base excision repair 
e
 Mismatch repair 
f
 Double strand break repair 
g
 Zinc homeostasis 
h
 Genes containing MRE sites 
i
 Oxidative stress 
j
 Keratinocyte proliferation/differentiation, cell survival 
k
 Others: ZNRD1, MGMT, HSPA6 (HSP70B), HSPD1 (HSP60), CYP1A1, CYP1B1 
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l
 Housekeeping genes used for normalisation 
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 UVB Zinc (II) + UVB 
Gene Symbol fold change (2
-ddCt
) p value
1
 fold change (2
-ddCt
) p value
1
 
TNF 28,83 0,05815 24,37 0,014558 
PTGS2 19,39 0,052279 18,10 0,004363 
IL8 18,26 0,011145 21,04 0,00227 
ATF3 9,30 0,026083 10,62 0,020249 
JUN
2
 8,68 ns 8,21 0,050386 
FOS
2
 6,04 ns 7,10 ns 
GADD45B 5,85 0,005414 6,57 0,012406 
CDKN1A
2
 4,21 ns 4,11 0,037189 
CCNE1 3,67 0,044125 4,56 0,022938 
SNAI2
2
 3,04 ns 3,42 0,003713 
HBEGF 2,71 0,001709 2,79 0,00898 
IL1B
2
 2,53 ns 2,43 0,018241 
DDIT3 1,78 ns 1,97 0,044236 
CYP1A1 1,62 0,042759 1,76 0,025693 
CEBPA 1,61 0,024664 1,66 ns 
SLC30A1 1,28 ns 2,94 0,032076 
MT1X 1,15 ns 4,33 0,01818 
MT2A 1,14 ns 3,89 5,58E-05 
MT1F 0,78 ns 21,92 0,000983 
DDB2 0,74 0,035138 0,84 ns 
ERCC2 0,71 0,002939 0,73 0,041664 
NTHL1 0,71 0,031694 0,77 ns 
RAD51 0,70 0,013263 0,85 ns 
CHEK1 0,64 0,053186 0,72 0,019469 
SMUG1 0,60 ns 0,58 0,015714 
TREX1 0,59 0,044764 0,64 0,032647 
POLB 0,56 0,006388 0,77 ns 
CHEK2 0,55 0,014411 0,54 0,024618 
ERCC5 0,51 0,040806 0,57 0,014313 
MSH2 0,50 0,010779 0,54 0,004747 
ERCC4 0,50 0,013892 0,55 0,000433 
ERCC3 0,49 0,017928 0,48 0,003888 
XRCC3 0,46 0,009467 0,46 0,00588 
HIPK2 0,46 0,015698 0,74 ns 
ITCH 0,45 0,005814 0,47 0,00756 
TRIM26 0,42 0,001248 0,47 0,000815 
ATM 0,41 0,009832 0,44 0,000551 
IGF1R 0,38 0,005486 0,39 0,000444 
XPC 0,37 0,002325 0,40 0,005501 
BCL2L1 0,36 0,00826 0,37 0,008226 
ATR 0,36 0,005014 0,38 0,001731 
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MSH6 0,35 0,000764 0,41 0,011031 
RAD52 0,33 0,001544 0,39 0,00087 
MTF1 0,32 0,013172 0,33 0,00492 
MDM2 0,30 0,00186 0,33 0,001146 
TP73 0,28 0,005793 0,25 0,001074 
VEGFC 0,27 0,003256 0,27 0,001116 
XRCC2 0,25 0,001383 0,26 0,000498 
NOTCH1 0,23 0,001808 0,26 0,000788 
SKIL 0,23 0,001938 0,27 0,000269 
APC 0,20 0,007314 0,20 0,006341 
BCL2 0,18 0,000877 0,12 0,002252 
CCNF 0,17 0,000928 0,21 0,001193 
MT1E 0,12 0,000225 0,30 0,002777 
Supplementary 2. Effect of Zn (II) pre-treatment on transcriptional changes induced by 
UVB irradiation 
The relative gene expression in HaCaT cells exposed to 20 mJ/cm
2
 UVB for 6 h or pre-treated 
with 100 µM ZnCl2 for 24 h and then UVB irradiated was measured and analysed by TLDA 
relative to untreated cells. 
ns, not significant p<0.05 
1
 with 2-tailed Student’s t test 
2
 at least ±2-fold differences in each experiment between treated and untreated cells 
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